20 Things To Know About Alzheimer's Disease

Please Help Support Alzheimer's Research Today!

Your Alzheimer's donation will help billions live without it.

Alzheimer's facts

( bapineuzumab )

Pfizer Inc research chief Mikael Dolsten said the company's experimental treatment for Alzheimer's disease is the drug industry's "best chance" to delay progression of the memory-robbing illness. Dolsten, speaking at the BIO CEO and investor conference in New York, stopped short of predicting whether the drug being developed with Johnson & Johnson would meet that goal. "This is so far the best chance the industry has for disease modification in Alzheimer's," he said. Dolsten said Pfizer's drug, bapineuzumab, had far more complete and compelling data from already finished mid-stage clinical trials than Eli Lilly and Co's solanezumab.

Both companies plan to release Phase III data in the second half of this year from their respective large trials. The drugs are meant to be the first to slow progression of Alzheimer's, a disease that affects an estimated 5 million Americans and more than 35 million people worldwide. "Bapineuzumab was the only one of these two that had significant Phase II data," Dolsten said, referring to the relatively brief 12-week trials Lilly conducted on solanezumab before moving it into large late-stage studies. Continue to read: reuters.com

Read more here: http://www.bnd.com/2012/02/07/2047945/obama-to-seek-more-alzheimers.html#storylink=cpy

TODAY'S PHOTO

Omega-3's linked to slower eye sight loss

A diet rich in omega-3 fatty acids in combination with vitamin A supplements may slow the decline in eye sight in people with retinitis pigmentosa, says a new study in the Archives of Ophthalmology. Read more: nutraingredients.com

Беларусь ТВ